1. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
- Author
-
Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W., Brümmendorf, T, Cortes, J, Milojkovic, D, Gambacorti-Passerini, C, Clark, R, le Coutre, P, Garcia-Gutierrez, V, Chuah, C, Kota, V, Lipton, J, Rousselot, P, Mauro, M, Hochhaus, A, Hurtado Monroy, R, Leip, E, Purcell, S, Yver, A, Viqueira, A, and Deininger, M
- Subjects
Cancer Research ,Aniline Compounds ,Antineoplastic Agents ,Hematology ,randomized controlled trials, haematological cancer, bosutinib, imatinib, chronic myeloid leukemia ,Treatment Outcome ,Oncology ,Leukemia, Myeloid, Chronic-Phase ,Nitriles ,Imatinib Mesylate ,Quinolines ,Humans ,ddc:610 ,Protein Kinase Inhibitors - Abstract
Leukemia : normal and malignant hemopoiesis 36(7), 1825-1833 (2022). doi:10.1038/s41375-022-01589-y, Published by Springer Nature, London
- Published
- 2022